<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02295813</url>
  </required_header>
  <id_info>
    <org_study_id>201101H-TOLPKE</org_study_id>
    <nct_id>NCT02295813</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics Study of FBF001</brief_title>
  <official_title>A Single Center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of One Single Intravenous Dose and 5-day Repeated Intravenous Doses of FBF001 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fab'entech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fab'entech</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the clinical and laboratory safety and to determine
      the pharmacokinetic profile of FBF001.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>The subjects will be followed during their hospitalization stay (2 days or 6 days) and up to an average of 3 weeks after hospitalization</time_frame>
    <description>mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG evaluation</measure>
    <time_frame>The subjects will be followed during their hospitalization stay (2 days or 6 days) and up to an average of 3 weeks after hospitalization</time_frame>
    <description>12-lead ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Haematology</measure>
    <time_frame>The subjects will be followed during their hospitalization stay (2 days or 6 days) and up to an average of 3 weeks after hospitalization</time_frame>
    <description>Normal values of haematology parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complement activation assay</measure>
    <time_frame>Before dosing, at the end of infusion and 2hours after the beginning</time_frame>
    <description>ng/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate</measure>
    <time_frame>The subjects will be followed during their hospitalization stay (2 days or 6 days) and up to an average of 3 weeks after hospitalization</time_frame>
    <description>bpm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral temperature</measure>
    <time_frame>The subjects will be followed during their hospitalization stay (2 days or 6 days) and up to an average of 3 weeks after hospitalization</time_frame>
    <description>Celcius degree</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body weight</measure>
    <time_frame>The subjects will be followed during their hospitalization stay (2 days or 6 days) and up to an average of 3 weeks after hospitalization</time_frame>
    <description>kg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood chemistry</measure>
    <time_frame>The subjects will be followed during their hospitalization stay (2 days or 6 days) and up to an average of 3 weeks after hospitalization</time_frame>
    <description>Normal values of blood chemistry parameters</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Avian Influenza</condition>
  <arm_group>
    <arm_group_label>FBF001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FBF001 must be administered by intravenous route during 1 hour. The dose must be calculated according to the body weight of the subject and diluted in sodium chloride 0.9%.
FBF001 is administered once during 1 day or once per day during 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo must be administered by intravenous route during 1 hour. It administered once during 1 day or once per day during 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FBF001</intervention_name>
    <arm_group_label>FBF001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sodium chloride 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subject between 21-40 years old

          -  with body mass index in the range 18 to 30 Kg/m2

        Exclusion Criteria:

          -  Any history or presence of clinically relevant cardiovascular, pulmonary,
             gastrointestinal, hepatic, renal, metabolic, haematological, neurological,
             osteo-muscular, articular, psychiatric, systemic, ocular, or infectious disease, or
             signs of acute illness

          -  Any vaccination within three months before the inclusion

          -  Any vaccination against H5N1 virus

          -  Planned receipt of any vaccine during the study

          -  Any infectious disease within the month before the inclusion

          -  Any history of animal proteins allergy, animal allergy and/or any drug, food and
             pollen allergy

          -  Who has received blood or plasma derivatives (human or animal) in the three months
             preceding the initiation of the study

          -  Any medication within 14 days before the inclusion or within 5 times the elimination
             half-life or pharmacodynamic half-life of that drug
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2014</study_first_submitted>
  <study_first_submitted_qc>November 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <last_update_submitted>November 17, 2014</last_update_submitted>
  <last_update_submitted_qc>November 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

